I Kalsekar
Johnson & Johnson
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by I Kalsekar.
Journal of Medical Economics | 2017
Sanjoy Roy; A Yoo; Sashi Yadalam; E. Fegelman; I Kalsekar; Ss Johnston
Abstract Aims: To compare economic and clinical outcomes between patients undergoing laparoscopic Roux-en-Y gastric bypass (LRY) or laparoscopic sleeve gastrectomy (LSG) with use of powered vs manual endoscopic surgical staplers. Materials and methods: Patients (aged ≥21 years) who underwent LRY or LSG during a hospital admission (January 1, 2012–September 30, 2015) were identified from the Premier Perspective Hospital Database. Use of powered vs manual staplers was identified from hospital administrative billing records. Multivariable analyses were used to compare the following outcomes between the powered and manual stapler groups, adjusting for patient and hospital characteristics and hospital-level clustering: hospital length of stay (LOS), total hospital costs, medical/surgical supply costs, room and board costs, operating room costs, operating room time, discharge status, bleeding/transfusion during the hospital admission, and 30, 60, and 90-day all-cause readmissions. Results: The powered and manual stapler groups comprised 9,851 patients (mean age = 44.6 years; 79.3% female) and 21,558 patients (mean age = 45.0 years; 78.0% female), respectively. In the multivariable analyses, adjusted mean hospital LOS was 2.1 days for both the powered and manual stapler groups (p = .981). Adjusted mean total hospital costs (
Health Economics Review | 2016
Varun Vaidya; Keyuri Adhikari; Jack Sheehan; I Kalsekar
12,415 vs
Journal of Medical Economics | 2018
Andrea Barnow; Laura Goldstein; I Kalsekar; Ray Liao; Rahul Khanna
13,547, p = .003), adjusted mean supply costs (
Jsls-journal of The Society of Laparoendoscopic Surgeons | 2017
Katherine Etter; Brad Davis; Sanjoy Roy; I Kalsekar; Andrew Yoo
4,629 vs
Journal of Knee Surgery | 2017
Katherine Etter; Jason Lerner; I Kalsekar; Carl de Moor; A Yoo; Michael Swank
5,217, p = .011), and adjusted mean operating room costs (
Health Economics Review | 2017
I Kalsekar; Chia-Wen Hsiao; Hang Cheng; Sashi Yadalam; Brian Po-Han Chen; Laura J Goldstein; A Yoo
4,126 vs
Advances in Therapy | 2016
Amanda M. Farr; John J. Sheehan; Matthew Brouillette; Stephen S. Johnston; I Kalsekar
4,413, p = .009) were significantly lower in the powered vs manual stapler group. The adjusted rate of bleeding and/or transfusion during the hospital admission (2.46% vs 3.22%, p = .025) was significantly lower in the powered vs manual stapler group. The adjusted rates of 30, 60, and 90-day all-cause readmissions were similar between the groups (all p > .05). Sub-analysis by manufacturer showed similar results. Limitations: This observational study cannot establish causal linkages. Conclusions: In this analysis of patients who underwent LRY or LSG, the use of powered staplers was associated with better economic outcomes, and a lower rate of bleeding/transfusion vs manual staplers in the real-world setting.
Value in Health | 2018
Jw Jarman; J March; Lj Goldstein; Ray Liao; I Kalsekar; Rahul Khanna; A Chitnis
ObjectivesSaxagliptin and sitagliptin are two commonly used dipeptidyl peptidase-4 (DPP-4) inhibitors. Little is known about their comparative effectiveness in the real world, particularly their impact on cost and resources use. The objective of this study was to analyze charges and resource use associated with saxagliptin and sitagliptin to understand the impact of these DPP-4 inhibitor treatment options in a real-world setting.MethodsThis was a retrospective, new-user study approved by the Institutional Review Board at the University of Toledo. Data were collected from a US insurance claims dataset (OptumInsight) for patients newly initiating treatment with saxagliptin or sitagliptin between January 1, 2010 and December 31, 2011. ICD-9 code 250 was used to identify patients with T2D. Overall and diabetes-related medical and pharmacy charges were observed. Inpatient hospitalizations were also compared. Propensity score matching was used to balance the cohorts of patients prescribed saxagliptin and sitagliptin. Appropriate univariate statistical tests were applied to the propensity-matched sample to examine differences in resource utilization outcomes. Statistical significance was evaluated at P < 0.05.ResultAfter the propensity score matching, each cohort included 7711 patients. Saxagliptin treatment was associated with lower overall charges (
Value in Health | 2018
Lj Goldstein; Andrea Barnow; M Daskiran; I Kalsekar; Rahul Khanna
13,292 vs
Value in Health | 2017
Rahul Khanna; I Kalsekar; Andrea Barnow; Ray Liao
14,032; P = 0.0023) and overall medical charges (